AI-extracted from the 10-Q filed 2026-05-12 — Q1 FY2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
AnaptysBio completed separation into two public companies on April 20, 2026, retaining Jemperli and imsidolimab royalty streams worth $25.6M in Q1 2026 revenue while shedding clinical-stage R&D.
Biggest Revenue Drivers
Jemperli royalties (non-cash)$24.6M+43% YoY
Increased GSK net sales of Jemperli and Zejula combination programs
Zejula royalties (non-cash)$0.9M0% YoY
Flat royalties from GSK's Zejula net sales under monetization agreement
Biggest Revenue Drivers
Total revenue: $25.6M-8% YoY
Jemperli royalties (non-cash)$24.6M+43% YoY
Increased GSK net sales of Jemperli and Zejula combination programs
Zejula royalties (non-cash)$0.9M0% YoY
Flat royalties from GSK's Zejula net sales under monetization agreement
Largest Expense Items
Research and development$34.0M-17% YoY
Decreased clinical expenses from rosnilimab Phase 2b wind-down; offset by ANB033 and ANB101 advancement
Non-cash interest expense for sale of future royalties$20.9M+16% YoY
Higher imputed interest on Jemperli and Zejula royalty monetization liabilities due to accelerated Sagard payments
Watch Items from the Filing
Substantial royalty concentration: Jemperli royalties represent 96% of collaboration revenue; dependent on GSK commercialization success and subject to competitive pressure from Keytruda and future biosimilars.
Ongoing litigation with GSK (Tesaro) over alleged breach of collaboration agreement filed November 2025; trial scheduled July 14, 2026; outcome could impact Jemperli royalty payments and patent rights.
Jemperli Royalty Monetization Agreement: Sagard has received $249.3M of $600-675M threshold as of March 31, 2026; acceleration of payments due to strong sales may shorten monetization period and reduce future flexibility.
Post-separation infrastructure: Company now operates as pure royalty collector with minimal R&D; depends on First Tracks for transition services but faces higher public company costs and reduced operational leverage.
Cash position of $286.5M (excluding investments) as of March 31, 2026 provides runway; however, management indicates sufficient resources for next 12 months only without near-term revenue growth from new collaborations.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
About ANAPTYSBIO, INC (ANAB): stock profile, AI score and financials
ANAPTYSBIO, INC (ANAB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ANAB at 72.0/100 on a composite quality score built from its SEC filings, placing it at rank #168 of 2,925 stocks — the top 10% of the AI-ranked universe. ANAB scores in the top quartile across balance sheet strength (99.5), profitability (99.2), revenue growth (98.5). Areas of concern include revenue scale (26.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 43.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ANAPTYSBIO, INC reports quarterly revenue of $27.5M, net income of $183.9M. Top institutional holders of ANAB by reported 13-F value include EcoR1 Capital, BlackRock, TANG CAPITAL MANAGEMENT, based on the most recent SEC filings. ANAB trades on the Nasdaq exchange and files with the SEC under CIK 1370053. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ANAPTYSBIO, INC directly from SEC EDGAR.